LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs JERUSALEM, Jan. 23, 2020 (GLOBE NEWSWIRE) -- LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based...

Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia Newark, NJ, April 12, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I...